Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 7/20 | 0.35 |
| ▸ | CCL5 | P13501 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641389 | 1.00 | CCR5 (0.35) | CCR5CCL5CHRM1DRD3DRD2 | |
| SCHEMBL640046 | 0.98 | CCR5 (0.36) | CCR5CCL5CHRM1DRD3HTR6 | |
| SCHEMBL640047 | 0.98 | CCR5 (0.36) | CCR5CCL5CHRM1DRD3HTR6 | |
| SCHEMBL641118 | 0.94 | ALDH1A1 (0.40) | CCR5CCL5MGLL | |
| SCHEMBL641096 | 0.94 | ALDH1A1 (0.40) | CCR5CCL5MGLL | |
| SCHEMBL641097 | 0.94 | ALDH1A1 (0.40) | CCR5CCL5MGLL | |
| SCHEMBL639985 | 0.93 | MEN1 (0.34) | CCR5CCL5CHRM1HSD11B1 | |
| SCHEMBL639986 | 0.93 | MEN1 (0.34) | CCR5CCL5CHRM1HSD11B1 | |
| SCHEMBL640474 | 0.92 | HRH2 (0.34) | CCR5CCL5CHRM1KDM2BMGLL | |
| SCHEMBL640475 | 0.92 | HRH2 (0.34) | CCR5CCL5CHRM1KDM2BMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | CCR5 3327/4885CCL5 2597/4885CHRM1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.